This study involved 26 randomized controlled trials, including 2375 individuals, and observed that treatment with silymarin was associated with a reduction in ALT (SMD = −12.39) and AST (SMD = −10.97) in NAFLD patients. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.